Ahmed Sallam
Concepts (448)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitrectomy | 32 | 2025 | 61 | 9.810 |
Why?
| | Phacoemulsification | 19 | 2026 | 36 | 9.050 |
Why?
| | Visual Acuity | 43 | 2026 | 155 | 9.010 |
Why?
| | Macular Edema | 18 | 2024 | 31 | 7.850 |
Why?
| | Triticum | 15 | 2026 | 19 | 7.170 |
Why?
| | Cataract | 14 | 2024 | 44 | 6.860 |
Why?
| | Cataract Extraction | 16 | 2026 | 33 | 6.780 |
Why?
| | Intraoperative Complications | 18 | 2026 | 114 | 6.220 |
Why?
| | Diabetic Retinopathy | 12 | 2026 | 50 | 5.490 |
Why?
| | Ophthalmology | 10 | 2026 | 34 | 5.310 |
Why?
| | Retinal Detachment | 15 | 2024 | 25 | 5.290 |
Why?
| | Uveitis | 14 | 2026 | 24 | 4.850 |
Why?
| | Tomography, Optical Coherence | 22 | 2025 | 114 | 4.760 |
Why?
| | Postoperative Complications | 19 | 2026 | 1099 | 4.200 |
Why?
| | Glaucoma | 9 | 2024 | 39 | 3.500 |
Why?
| | Lens Implantation, Intraocular | 11 | 2026 | 25 | 3.290 |
Why?
| | Retrospective Studies | 64 | 2026 | 6819 | 3.260 |
Why?
| | Glucocorticoids | 16 | 2024 | 236 | 3.140 |
Why?
| | Endophthalmitis | 11 | 2023 | 25 | 3.060 |
Why?
| | Epiretinal Membrane | 5 | 2024 | 10 | 3.040 |
Why?
| | Droughts | 9 | 2026 | 15 | 2.940 |
Why?
| | Papilledema | 5 | 2026 | 28 | 2.670 |
Why?
| | Eye Infections, Bacterial | 8 | 2024 | 29 | 2.650 |
Why?
| | Genotype | 15 | 2026 | 563 | 2.640 |
Why?
| | Humans | 144 | 2026 | 53230 | 2.640 |
Why?
| | Dexamethasone | 9 | 2023 | 429 | 2.540 |
Why?
| | Comprehension | 7 | 2024 | 115 | 2.310 |
Why?
| | Drug Implants | 9 | 2023 | 35 | 2.300 |
Why?
| | Intraocular Pressure | 12 | 2026 | 65 | 2.130 |
Why?
| | Hordeum | 4 | 2022 | 6 | 2.130 |
Why?
| | Syphilis | 5 | 2024 | 21 | 2.080 |
Why?
| | Fluorescein Angiography | 7 | 2024 | 36 | 2.080 |
Why?
| | Stress, Physiological | 8 | 2026 | 184 | 2.020 |
Why?
| | Aged | 50 | 2026 | 10429 | 1.950 |
Why?
| | Vitreoretinal Surgery | 5 | 2024 | 8 | 1.940 |
Why?
| | Middle Aged | 53 | 2026 | 13419 | 1.870 |
Why?
| | Diabetes Mellitus | 4 | 2022 | 321 | 1.820 |
Why?
| | Vicia faba | 2 | 2025 | 2 | 1.810 |
Why?
| | Eye Infections, Fungal | 6 | 2021 | 20 | 1.770 |
Why?
| | Retinal Vessels | 3 | 2024 | 20 | 1.760 |
Why?
| | Retinal Vein Occlusion | 6 | 2023 | 13 | 1.760 |
Why?
| | Male | 72 | 2026 | 27435 | 1.700 |
Why?
| | Databases, Factual | 13 | 2026 | 742 | 1.670 |
Why?
| | Retinitis Pigmentosa | 2 | 2024 | 8 | 1.660 |
Why?
| | Polymorphism, Single Nucleotide | 8 | 2026 | 505 | 1.610 |
Why?
| | Angiogenesis Inhibitors | 8 | 2026 | 186 | 1.580 |
Why?
| | Female | 69 | 2026 | 28782 | 1.580 |
Why?
| | Aged, 80 and over | 28 | 2026 | 3494 | 1.540 |
Why?
| | Retinal Diseases | 8 | 2025 | 59 | 1.510 |
Why?
| | Quantitative Trait Loci | 7 | 2026 | 53 | 1.500 |
Why?
| | Eye Diseases | 4 | 2025 | 36 | 1.490 |
Why?
| | Pseudophakia | 6 | 2024 | 12 | 1.480 |
Why?
| | Genome-Wide Association Study | 8 | 2026 | 184 | 1.470 |
Why?
| | Vision Disorders | 6 | 2026 | 61 | 1.460 |
Why?
| | Intravitreal Injections | 16 | 2026 | 35 | 1.370 |
Why?
| | Phenotype | 11 | 2026 | 803 | 1.350 |
Why?
| | Retinal Perforations | 5 | 2025 | 8 | 1.340 |
Why?
| | Fluorocarbons | 3 | 2023 | 65 | 1.340 |
Why?
| | Fibrin | 2 | 2023 | 10 | 1.320 |
Why?
| | Adult | 38 | 2026 | 14534 | 1.310 |
Why?
| | Paracentesis | 2 | 2023 | 13 | 1.310 |
Why?
| | Sclera | 2 | 2024 | 5 | 1.260 |
Why?
| | Germination | 4 | 2026 | 8 | 1.260 |
Why?
| | Follow-Up Studies | 17 | 2026 | 2318 | 1.250 |
Why?
| | Tissue Plasminogen Activator | 2 | 2023 | 108 | 1.230 |
Why?
| | Macular Degeneration | 4 | 2024 | 28 | 1.190 |
Why?
| | Lenses, Intraocular | 2 | 2022 | 7 | 1.170 |
Why?
| | Egypt | 8 | 2026 | 23 | 1.170 |
Why?
| | Gene-Environment Interaction | 3 | 2025 | 41 | 1.130 |
Why?
| | Choroid | 5 | 2024 | 14 | 1.090 |
Why?
| | Fractals | 2 | 2024 | 9 | 1.070 |
Why?
| | Internet | 3 | 2024 | 265 | 1.060 |
Why?
| | Retina | 7 | 2024 | 76 | 1.060 |
Why?
| | Seeds | 3 | 2026 | 21 | 1.050 |
Why?
| | Ocular Hypertension | 3 | 2026 | 10 | 1.050 |
Why?
| | Iris Diseases | 3 | 2020 | 4 | 1.040 |
Why?
| | Wet Macular Degeneration | 3 | 2022 | 7 | 1.040 |
Why?
| | Incidence | 16 | 2026 | 1085 | 1.040 |
Why?
| | Risk Factors | 16 | 2026 | 4017 | 1.000 |
Why?
| | Candidiasis | 3 | 2021 | 114 | 1.000 |
Why?
| | Linkage Disequilibrium | 4 | 2024 | 41 | 0.980 |
Why?
| | Eye Injuries | 4 | 2024 | 27 | 0.960 |
Why?
| | Societies, Medical | 3 | 2019 | 207 | 0.960 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 130 | 0.940 |
Why?
| | Pre-Eclampsia | 1 | 2026 | 47 | 0.930 |
Why?
| | Endotamponade | 5 | 2025 | 10 | 0.920 |
Why?
| | Retinopathy of Prematurity | 1 | 2025 | 16 | 0.920 |
Why?
| | Genetic Variation | 4 | 2024 | 223 | 0.910 |
Why?
| | Sarcoidosis | 1 | 2026 | 44 | 0.910 |
Why?
| | Plant Diseases | 3 | 2019 | 13 | 0.910 |
Why?
| | Muscarinic Agonists | 1 | 2024 | 10 | 0.880 |
Why?
| | Pilocarpine | 1 | 2024 | 20 | 0.880 |
Why?
| | Retinitis | 2 | 2022 | 5 | 0.870 |
Why?
| | Lens Subluxation | 1 | 2024 | 2 | 0.870 |
Why?
| | Limbus Corneae | 1 | 2024 | 8 | 0.860 |
Why?
| | Lighting | 1 | 2024 | 5 | 0.840 |
Why?
| | Ciliary Body | 1 | 2024 | 3 | 0.840 |
Why?
| | Adaptation, Physiological | 2 | 2024 | 109 | 0.840 |
Why?
| | Anterior Chamber | 1 | 2023 | 5 | 0.830 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2025 | 150 | 0.830 |
Why?
| | Clinical Competence | 2 | 2026 | 406 | 0.830 |
Why?
| | Child | 20 | 2026 | 7379 | 0.820 |
Why?
| | Laser Coagulation | 1 | 2024 | 26 | 0.820 |
Why?
| | Lens, Crystalline | 1 | 2024 | 19 | 0.820 |
Why?
| | Education, Medical, Graduate | 1 | 2026 | 219 | 0.820 |
Why?
| | Triamcinolone Acetonide | 5 | 2011 | 15 | 0.810 |
Why?
| | Panuveitis | 2 | 2021 | 6 | 0.810 |
Why?
| | Basement Membrane | 2 | 2025 | 19 | 0.810 |
Why?
| | Anesthesia, General | 3 | 2024 | 99 | 0.810 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2026 | 189 | 0.790 |
Why?
| | Endoscopy | 1 | 2024 | 128 | 0.780 |
Why?
| | Reproducibility of Results | 9 | 2024 | 1219 | 0.770 |
Why?
| | Cocaine-Related Disorders | 1 | 2025 | 206 | 0.770 |
Why?
| | Occlusive Dressings | 1 | 2022 | 6 | 0.760 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2026 | 591 | 0.760 |
Why?
| | State Medicine | 5 | 2023 | 21 | 0.750 |
Why?
| | HIV Seropositivity | 1 | 2022 | 28 | 0.740 |
Why?
| | Rift Valley Fever | 1 | 2022 | 1 | 0.740 |
Why?
| | Smoking Cessation | 1 | 2025 | 325 | 0.740 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2022 | 5 | 0.740 |
Why?
| | Eye Foreign Bodies | 1 | 2022 | 6 | 0.730 |
Why?
| | Patient Education as Topic | 5 | 2024 | 325 | 0.730 |
Why?
| | Enbucrilate | 1 | 2021 | 6 | 0.720 |
Why?
| | Smoking | 1 | 2025 | 526 | 0.720 |
Why?
| | Tissue Adhesives | 1 | 2021 | 15 | 0.720 |
Why?
| | Artificial Intelligence | 1 | 2023 | 131 | 0.720 |
Why?
| | United States | 14 | 2026 | 5409 | 0.710 |
Why?
| | Vitreous Detachment | 2 | 2025 | 2 | 0.710 |
Why?
| | Varicose Veins | 2 | 2019 | 18 | 0.690 |
Why?
| | Treatment Outcome | 16 | 2025 | 5595 | 0.690 |
Why?
| | Candida | 4 | 2020 | 63 | 0.670 |
Why?
| | Choroiditis | 1 | 2020 | 9 | 0.670 |
Why?
| | Health Services Accessibility | 1 | 2025 | 477 | 0.660 |
Why?
| | Retinal Vein | 2 | 2019 | 3 | 0.630 |
Why?
| | Cross-Sectional Studies | 8 | 2025 | 1723 | 0.620 |
Why?
| | Photography | 4 | 2013 | 32 | 0.620 |
Why?
| | Eyeglasses | 1 | 2019 | 9 | 0.620 |
Why?
| | Surgical Instruments | 1 | 2019 | 29 | 0.610 |
Why?
| | Trichoderma | 1 | 2019 | 1 | 0.610 |
Why?
| | Crohn Disease | 1 | 2020 | 116 | 0.600 |
Why?
| | Suture Techniques | 2 | 2022 | 57 | 0.590 |
Why?
| | Vitreous Body | 6 | 2025 | 19 | 0.590 |
Why?
| | Laser Therapy | 1 | 2019 | 75 | 0.590 |
Why?
| | Chromosome Mapping | 6 | 2026 | 145 | 0.580 |
Why?
| | Fovea Centralis | 1 | 2018 | 6 | 0.580 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 145 | 0.580 |
Why?
| | National Health Programs | 2 | 2015 | 19 | 0.560 |
Why?
| | HIV Infections | 1 | 2022 | 402 | 0.550 |
Why?
| | Prevalence | 5 | 2026 | 1034 | 0.540 |
Why?
| | Fluocinolone Acetonide | 1 | 2017 | 5 | 0.540 |
Why?
| | Ophthalmic Solutions | 3 | 2024 | 20 | 0.540 |
Why?
| | Air | 2 | 2016 | 22 | 0.520 |
Why?
| | Prospective Studies | 8 | 2024 | 2411 | 0.520 |
Why?
| | Minerals | 1 | 2016 | 26 | 0.500 |
Why?
| | Young Adult | 11 | 2026 | 4511 | 0.490 |
Why?
| | Sodium Chloride | 1 | 2016 | 53 | 0.490 |
Why?
| | Chorioretinitis | 3 | 2024 | 10 | 0.490 |
Why?
| | Acetates | 1 | 2016 | 51 | 0.480 |
Why?
| | Dissection | 1 | 2016 | 14 | 0.480 |
Why?
| | Algorithms | 2 | 2023 | 667 | 0.480 |
Why?
| | Child, Preschool | 11 | 2026 | 4162 | 0.470 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2016 | 21 | 0.470 |
Why?
| | Anesthesia, Local | 1 | 2015 | 18 | 0.460 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 2 | 2020 | 7 | 0.450 |
Why?
| | Registries | 2 | 2018 | 652 | 0.450 |
Why?
| | Glaucoma, Open-Angle | 2 | 2026 | 26 | 0.440 |
Why?
| | Microvessels | 2 | 2024 | 36 | 0.420 |
Why?
| | Consumer Health Information | 2 | 2024 | 20 | 0.420 |
Why?
| | Device Removal | 1 | 2014 | 89 | 0.400 |
Why?
| | Treponema pallidum | 3 | 2024 | 9 | 0.390 |
Why?
| | Macula Lutea | 2 | 2025 | 5 | 0.390 |
Why?
| | Models, Theoretical | 1 | 2014 | 180 | 0.390 |
Why?
| | Iris | 3 | 2022 | 6 | 0.380 |
Why?
| | Alleles | 3 | 2023 | 277 | 0.360 |
Why?
| | Scleral Buckling | 3 | 2023 | 5 | 0.350 |
Why?
| | Physical Examination | 2 | 2013 | 96 | 0.350 |
Why?
| | Optic Disk | 2 | 2021 | 23 | 0.350 |
Why?
| | Mydriatics | 1 | 2011 | 12 | 0.350 |
Why?
| | Microscopy | 1 | 2011 | 47 | 0.340 |
Why?
| | Electronic Health Records | 4 | 2024 | 287 | 0.340 |
Why?
| | Seasons | 2 | 2022 | 92 | 0.330 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2023 | 11 | 0.310 |
Why?
| | Fibrinolytic Agents | 2 | 2023 | 132 | 0.300 |
Why?
| | Intraoperative Period | 2 | 2019 | 46 | 0.300 |
Why?
| | Basidiomycota | 2 | 2019 | 3 | 0.300 |
Why?
| | Vision, Low | 2 | 2022 | 9 | 0.300 |
Why?
| | Adolescent | 11 | 2026 | 6907 | 0.300 |
Why?
| | Disease Resistance | 2 | 2019 | 10 | 0.300 |
Why?
| | Anti-Bacterial Agents | 5 | 2024 | 830 | 0.300 |
Why?
| | Fundus Oculi | 3 | 2024 | 26 | 0.300 |
Why?
| | Lens Capsule, Crystalline | 2 | 2016 | 2 | 0.300 |
Why?
| | Chromosomes, Plant | 3 | 2024 | 5 | 0.290 |
Why?
| | Tonometry, Ocular | 2 | 2024 | 8 | 0.290 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2008 | 27 | 0.280 |
Why?
| | Silicone Oils | 3 | 2023 | 3 | 0.280 |
Why?
| | Eye Infections, Viral | 1 | 2008 | 3 | 0.280 |
Why?
| | Ocular Hypotension | 1 | 2008 | 2 | 0.280 |
Why?
| | Eye Infections, Parasitic | 1 | 2008 | 3 | 0.280 |
Why?
| | Choroid Neoplasms | 1 | 2007 | 6 | 0.270 |
Why?
| | Suction | 1 | 2008 | 22 | 0.270 |
Why?
| | Teaching Materials | 2 | 2024 | 31 | 0.270 |
Why?
| | Physicians, Family | 1 | 2008 | 62 | 0.270 |
Why?
| | Surgical Flaps | 2 | 2025 | 110 | 0.260 |
Why?
| | Eye Burns | 1 | 2007 | 2 | 0.260 |
Why?
| | Sulfonamides | 1 | 2008 | 139 | 0.260 |
Why?
| | Hyaluronic Acid | 1 | 2007 | 39 | 0.260 |
Why?
| | Anti-Infective Agents | 1 | 2008 | 107 | 0.250 |
Why?
| | Zinc Oxide | 1 | 2026 | 6 | 0.240 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2026 | 1 | 0.240 |
Why?
| | Genetic Markers | 2 | 2024 | 104 | 0.240 |
Why?
| | Schistosomiasis mansoni | 1 | 2026 | 2 | 0.240 |
Why?
| | Horner Syndrome | 1 | 2026 | 6 | 0.240 |
Why?
| | Germany | 1 | 2025 | 26 | 0.240 |
Why?
| | Recombinant Fusion Proteins | 2 | 2026 | 175 | 0.240 |
Why?
| | Neuroblastoma | 1 | 2026 | 55 | 0.240 |
Why?
| | Vaccination | 3 | 2024 | 310 | 0.240 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2026 | 91 | 0.230 |
Why?
| | Prostaglandins, Synthetic | 1 | 2024 | 1 | 0.220 |
Why?
| | Dry Eye Syndromes | 1 | 2024 | 11 | 0.220 |
Why?
| | Salicylic Acid | 1 | 2024 | 6 | 0.220 |
Why?
| | Administration, Topical | 1 | 2024 | 62 | 0.220 |
Why?
| | Trabeculectomy | 1 | 2024 | 11 | 0.220 |
Why?
| | Genes, Plant | 1 | 2024 | 11 | 0.220 |
Why?
| | Glaucoma Drainage Implants | 1 | 2024 | 8 | 0.220 |
Why?
| | Melanoma | 1 | 2007 | 277 | 0.220 |
Why?
| | Cohort Studies | 2 | 2022 | 1557 | 0.220 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2024 | 3 | 0.210 |
Why?
| | Syphilis Serodiagnosis | 1 | 2024 | 4 | 0.210 |
Why?
| | Genome, Plant | 1 | 2024 | 10 | 0.210 |
Why?
| | Abducens Nerve Diseases | 1 | 2024 | 7 | 0.210 |
Why?
| | Garlic | 1 | 2024 | 5 | 0.210 |
Why?
| | Proanthocyanidins | 1 | 2024 | 4 | 0.210 |
Why?
| | Ciliary Arteries | 1 | 2024 | 2 | 0.210 |
Why?
| | Burns, Chemical | 1 | 2024 | 9 | 0.210 |
Why?
| | Haplotypes | 1 | 2024 | 96 | 0.210 |
Why?
| | Nebraska | 2 | 2021 | 7 | 0.210 |
Why?
| | Infant | 6 | 2026 | 3805 | 0.210 |
Why?
| | Pseudotumor Cerebri | 1 | 2024 | 24 | 0.210 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 523 | 0.210 |
Why?
| | Search Engine | 1 | 2023 | 11 | 0.210 |
Why?
| | Propensity Score | 1 | 2024 | 170 | 0.200 |
Why?
| | Tattooing | 1 | 2023 | 5 | 0.200 |
Why?
| | Geographic Atrophy | 1 | 2023 | 2 | 0.200 |
Why?
| | Sex Workers | 1 | 2023 | 2 | 0.200 |
Why?
| | Inflammation | 3 | 2022 | 652 | 0.200 |
Why?
| | Cultural Diversity | 1 | 2023 | 37 | 0.200 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 124 | 0.200 |
Why?
| | Odds Ratio | 1 | 2025 | 567 | 0.200 |
Why?
| | Fibrinolysin | 1 | 2023 | 2 | 0.200 |
Why?
| | Self Report | 1 | 2024 | 225 | 0.200 |
Why?
| | Schools, Medical | 1 | 2023 | 68 | 0.200 |
Why?
| | Retreatment | 2 | 2014 | 60 | 0.200 |
Why?
| | Drainage | 1 | 2023 | 92 | 0.200 |
Why?
| | ROC Curve | 1 | 2023 | 246 | 0.200 |
Why?
| | Dementia | 1 | 2024 | 141 | 0.190 |
Why?
| | Patient Selection | 1 | 2024 | 273 | 0.190 |
Why?
| | Faculty, Medical | 1 | 2023 | 92 | 0.190 |
Why?
| | Disease Progression | 1 | 2025 | 880 | 0.190 |
Why?
| | Vision Screening | 1 | 2022 | 11 | 0.190 |
Why?
| | Feasibility Studies | 1 | 2024 | 411 | 0.190 |
Why?
| | Subretinal Fluid | 1 | 2022 | 2 | 0.190 |
Why?
| | Blood-Retinal Barrier | 1 | 2022 | 6 | 0.190 |
Why?
| | Disease Management | 2 | 2021 | 187 | 0.190 |
Why?
| | Health Literacy | 4 | 2024 | 132 | 0.190 |
Why?
| | Sudan | 1 | 2022 | 2 | 0.190 |
Why?
| | Privacy | 1 | 2022 | 20 | 0.190 |
Why?
| | Myocardial Infarction | 1 | 2026 | 445 | 0.180 |
Why?
| | Cyanoacrylates | 1 | 2021 | 5 | 0.180 |
Why?
| | Polymerase Chain Reaction | 1 | 2023 | 452 | 0.180 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2021 | 13 | 0.180 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2015 | 238 | 0.180 |
Why?
| | Prednisone | 1 | 2022 | 101 | 0.180 |
Why?
| | Eye Abnormalities | 1 | 2021 | 25 | 0.180 |
Why?
| | Vision, Ocular | 1 | 2021 | 11 | 0.180 |
Why?
| | Eye | 1 | 2021 | 29 | 0.170 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 867 | 0.170 |
Why?
| | Disease Outbreaks | 1 | 2022 | 120 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 1180 | 0.170 |
Why?
| | Pregnancy | 2 | 2026 | 2608 | 0.170 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 224 | 0.170 |
Why?
| | Prolapse | 1 | 2020 | 7 | 0.170 |
Why?
| | Fungemia | 1 | 2021 | 38 | 0.170 |
Why?
| | Microsatellite Repeats | 1 | 2020 | 41 | 0.170 |
Why?
| | Stroke | 1 | 2026 | 520 | 0.170 |
Why?
| | Ecosystem | 1 | 2022 | 99 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 630 | 0.170 |
Why?
| | Internship and Residency | 1 | 2026 | 439 | 0.170 |
Why?
| | Animals | 4 | 2026 | 13526 | 0.170 |
Why?
| | Oximetry | 2 | 2011 | 65 | 0.160 |
Why?
| | Ophthalmoscopy | 1 | 2020 | 17 | 0.160 |
Why?
| | Swine | 1 | 2021 | 440 | 0.160 |
Why?
| | Retinal Pigment Epithelium | 1 | 2020 | 14 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2022 | 212 | 0.160 |
Why?
| | Nanoparticles | 1 | 2021 | 133 | 0.160 |
Why?
| | Bacteria | 1 | 2022 | 226 | 0.160 |
Why?
| | Blindness | 2 | 2022 | 33 | 0.160 |
Why?
| | Substance Abuse, Intravenous | 1 | 2020 | 44 | 0.160 |
Why?
| | Fusariosis | 1 | 2019 | 6 | 0.150 |
Why?
| | Plant Roots | 1 | 2019 | 26 | 0.150 |
Why?
| | Fusarium | 1 | 2019 | 31 | 0.150 |
Why?
| | Hepatitis C | 1 | 2020 | 82 | 0.150 |
Why?
| | Referral and Consultation | 3 | 2013 | 299 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2022 | 346 | 0.150 |
Why?
| | Emergencies | 2 | 2009 | 78 | 0.150 |
Why?
| | Antibiotic Prophylaxis | 1 | 2019 | 65 | 0.140 |
Why?
| | MicroRNAs | 1 | 2022 | 397 | 0.140 |
Why?
| | Equipment Design | 1 | 2019 | 290 | 0.140 |
Why?
| | Water | 1 | 2019 | 87 | 0.140 |
Why?
| | Gaucher Disease | 1 | 2018 | 16 | 0.140 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 118 | 0.140 |
Why?
| | Genetic Linkage | 1 | 2017 | 25 | 0.140 |
Why?
| | Recurrence | 2 | 2011 | 694 | 0.140 |
Why?
| | Infant, Newborn | 1 | 2025 | 2913 | 0.140 |
Why?
| | Sulfur Hexafluoride | 1 | 2017 | 3 | 0.140 |
Why?
| | Treatment Failure | 1 | 2018 | 119 | 0.130 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 405 | 0.130 |
Why?
| | Eye Diseases, Hereditary | 1 | 2017 | 5 | 0.130 |
Why?
| | Inheritance Patterns | 1 | 2017 | 22 | 0.130 |
Why?
| | Contrast Media | 1 | 2018 | 178 | 0.130 |
Why?
| | Penicillins | 1 | 2017 | 32 | 0.130 |
Why?
| | Carbonic Anhydrase Inhibitors | 2 | 2024 | 3 | 0.130 |
Why?
| | Fatty Acids | 1 | 2018 | 154 | 0.130 |
Why?
| | Risk Assessment | 2 | 2026 | 1368 | 0.130 |
Why?
| | Time Factors | 3 | 2020 | 2991 | 0.120 |
Why?
| | Microsurgery | 2 | 2024 | 32 | 0.120 |
Why?
| | Drug Combinations | 1 | 2016 | 138 | 0.120 |
Why?
| | Philippines | 1 | 2015 | 9 | 0.120 |
Why?
| | Video Recording | 1 | 2016 | 81 | 0.120 |
Why?
| | India | 1 | 2015 | 59 | 0.120 |
Why?
| | Anesthetics, General | 1 | 2015 | 4 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1367 | 0.110 |
Why?
| | Visually Impaired Persons | 1 | 2015 | 1 | 0.110 |
Why?
| | England | 2 | 2012 | 57 | 0.110 |
Why?
| | Anesthetics, Local | 1 | 2015 | 77 | 0.110 |
Why?
| | Acute Disease | 2 | 2021 | 393 | 0.110 |
Why?
| | Reading | 2 | 2024 | 74 | 0.100 |
Why?
| | Microscopy, Acoustic | 1 | 2013 | 3 | 0.100 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1038 | 0.100 |
Why?
| | Language | 2 | 2024 | 147 | 0.100 |
Why?
| | Glaucoma, Neovascular | 1 | 2012 | 2 | 0.100 |
Why?
| | Infusions, Intravenous | 2 | 2017 | 211 | 0.100 |
Why?
| | Syndrome | 2 | 2011 | 248 | 0.090 |
Why?
| | Mutation | 1 | 2017 | 1337 | 0.090 |
Why?
| | Muscle Hypotonia | 1 | 2011 | 23 | 0.090 |
Why?
| | Risperidone | 1 | 2011 | 25 | 0.080 |
Why?
| | Eye Hemorrhage | 1 | 2010 | 1 | 0.080 |
Why?
| | Cranial Sinuses | 1 | 2010 | 8 | 0.080 |
Why?
| | Carotid Artery Injuries | 1 | 2010 | 12 | 0.080 |
Why?
| | Arteriovenous Fistula | 1 | 2010 | 28 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2011 | 164 | 0.080 |
Why?
| | Prostaglandins F, Synthetic | 1 | 2009 | 1 | 0.080 |
Why?
| | Antipsychotic Agents | 1 | 2011 | 233 | 0.070 |
Why?
| | Prednisolone | 1 | 2009 | 56 | 0.070 |
Why?
| | Acetazolamide | 1 | 2008 | 16 | 0.070 |
Why?
| | Oxygen | 1 | 2011 | 338 | 0.070 |
Why?
| | Pupil | 1 | 2008 | 28 | 0.070 |
Why?
| | Vitreous Hemorrhage | 1 | 2008 | 3 | 0.070 |
Why?
| | Mass Screening | 1 | 2011 | 362 | 0.070 |
Why?
| | Prostatic Hyperplasia | 1 | 2008 | 39 | 0.070 |
Why?
| | Injections | 1 | 2008 | 59 | 0.070 |
Why?
| | Models, Biological | 1 | 2011 | 737 | 0.070 |
Why?
| | Electroretinography | 2 | 2018 | 18 | 0.070 |
Why?
| | Cefuroxime | 1 | 2007 | 3 | 0.070 |
Why?
| | Cefazolin | 1 | 2007 | 10 | 0.070 |
Why?
| | Capsulorhexis | 1 | 2007 | 1 | 0.070 |
Why?
| | Rupture | 1 | 2007 | 24 | 0.070 |
Why?
| | Astigmatism | 1 | 2007 | 5 | 0.070 |
Why?
| | Neoplasm Metastasis | 1 | 2007 | 237 | 0.060 |
Why?
| | Chronic Disease | 1 | 2009 | 580 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2026 | 26 | 0.060 |
Why?
| | Schistosoma mansoni | 1 | 2026 | 2 | 0.060 |
Why?
| | Praziquantel | 1 | 2026 | 4 | 0.060 |
Why?
| | Anthelmintics | 1 | 2026 | 13 | 0.060 |
Why?
| | Chlorophyll | 1 | 2024 | 14 | 0.060 |
Why?
| | Tissue Adhesions | 1 | 2025 | 37 | 0.050 |
Why?
| | Dehydration | 1 | 2024 | 26 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 46 | 0.050 |
Why?
| | Reagins | 1 | 2024 | 3 | 0.050 |
Why?
| | Posterior Eye Segment | 1 | 2024 | 3 | 0.050 |
Why?
| | Sex Distribution | 1 | 2024 | 140 | 0.050 |
Why?
| | Prosthesis Implantation | 1 | 2024 | 49 | 0.050 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 29 | 0.050 |
Why?
| | Rumen | 1 | 2024 | 1 | 0.050 |
Why?
| | Tannins | 1 | 2024 | 3 | 0.050 |
Why?
| | Fermentation | 1 | 2024 | 14 | 0.050 |
Why?
| | Goats | 1 | 2024 | 14 | 0.050 |
Why?
| | Diplopia | 1 | 2024 | 20 | 0.050 |
Why?
| | Animal Feed | 1 | 2024 | 55 | 0.050 |
Why?
| | Antifungal Agents | 1 | 2006 | 350 | 0.050 |
Why?
| | Anesthesia | 1 | 2024 | 67 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2024 | 192 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2023 | 54 | 0.050 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 15 | 0.050 |
Why?
| | Traction | 1 | 2021 | 7 | 0.050 |
Why?
| | Reoperation | 2 | 2014 | 476 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 623 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2023 | 221 | 0.040 |
Why?
| | Atrophy | 1 | 2020 | 48 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 530 | 0.040 |
Why?
| | Plant Stems | 1 | 2019 | 13 | 0.040 |
Why?
| | Diet | 1 | 2024 | 610 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 97 | 0.040 |
Why?
| | Pandemics | 1 | 2024 | 595 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2023 | 312 | 0.040 |
Why?
| | Europe | 1 | 2019 | 91 | 0.040 |
Why?
| | Molecular Sequence Annotation | 1 | 2018 | 28 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2022 | 868 | 0.040 |
Why?
| | Administration, Oral | 2 | 2011 | 456 | 0.040 |
Why?
| | Glucosylceramidase | 1 | 2018 | 8 | 0.040 |
Why?
| | Enzyme Replacement Therapy | 1 | 2018 | 17 | 0.040 |
Why?
| | Visual Fields | 1 | 2018 | 41 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 488 | 0.030 |
Why?
| | Inbreeding | 1 | 2017 | 4 | 0.030 |
Why?
| | Crosses, Genetic | 1 | 2017 | 33 | 0.030 |
Why?
| | Bread | 1 | 2017 | 4 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2017 | 19 | 0.030 |
Why?
| | Prone Position | 1 | 2017 | 29 | 0.030 |
Why?
| | Genes, Recessive | 1 | 2017 | 16 | 0.030 |
Why?
| | Consanguinity | 1 | 2017 | 18 | 0.030 |
Why?
| | Heterozygote | 1 | 2017 | 89 | 0.030 |
Why?
| | Pedigree | 1 | 2017 | 128 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 489 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 179 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2017 | 124 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 130 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 180 | 0.030 |
Why?
| | Rupture, Spontaneous | 1 | 2016 | 19 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 502 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 659 | 0.030 |
Why?
| | Choroidal Neovascularization | 1 | 2013 | 19 | 0.030 |
Why?
| | Age Distribution | 1 | 2013 | 175 | 0.020 |
Why?
| | Gonioscopy | 1 | 2012 | 3 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2012 | 158 | 0.020 |
Why?
| | Retinal Artery | 1 | 2011 | 4 | 0.020 |
Why?
| | Coloring Agents | 1 | 2011 | 65 | 0.020 |
Why?
| | Indocyanine Green | 1 | 2011 | 29 | 0.020 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2011 | 9 | 0.020 |
Why?
| | Angiography | 1 | 2011 | 114 | 0.020 |
Why?
| | Dopamine Antagonists | 1 | 2011 | 22 | 0.020 |
Why?
| | Injections, Intraocular | 1 | 2010 | 2 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2011 | 112 | 0.020 |
Why?
| | Methylprednisolone | 1 | 2010 | 41 | 0.020 |
Why?
| | Orbit | 1 | 2010 | 26 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2011 | 122 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 116 | 0.020 |
Why?
| | Schizophrenia | 1 | 2011 | 254 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2011 | 253 | 0.020 |
Why?
| | Sweden | 1 | 2007 | 11 | 0.020 |
Why?
|
|
Sallam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|